Gadobutrol

Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. Like other GBCA, gadobutrol usage carries the risk of nephrogenic systemic fibrosis (NSF) due to the dissociation of gadolinium from the chelates, although gadobutrol tends to have a lower risk of NSF thanks to the macrocyclic structures that limit dechelation of gadolinium. Its therapeutic use is listed as diagnostic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Gadovist and Gadobutran. Its PubChem CID is 6102852.

CAS No 770691-21-9
Molecular Formula C18H31GdN4O9
Molecular Weight 604.7 g/mol
Synonyms 2-[4,10-bis(carboxylatomethyl)-7-[(2R,3S)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+)

Frequently Asked Questions